Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Inhibrx Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Inhibrx Biosciences, Inc.

INBX

Inhibrx Biosciences, Inc.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing innovative biologic therapies using proprietary protein engineering platforms. Its focus includes oncology and immunotherapy, with pipeline candidates like ozekibart (INBRX-109) targeting cancer cell death pathways and INBRX-106 enhancing T-cell responses. The company aims to address high unmet medical needs through targeted, differentiated biologics for cancer and immune-related diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Inhibrx Biosciences, Inc.

1
1
Inhibrx Biosciences, Inc. Inhibrx Biosciences Reports $33.4 Million Net Loss, Improves Operating Expenses in Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Inhibrx Biosciences, Inc. Inhibrx Biosciences Reports $1.3M Revenue in Q3 2025, Net Loss Decreases to $35.3M

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Inhibrx Biosciences, Inc. Inhibrx Biosciences Reports $1.3M Revenue in Q2 2025, Faces $28.7M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Inhibrx Biosciences, Inc. Inhibrx Biosciences Reports $43.3 Million Net Loss in Q1 2025, Reduces Operating Expenses by 42%

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Inhibrx Biosciences, Inc. Inhibrx Biosciences Reports Significant Financial Changes, Net Income Turnaround in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments